[0001] The present invention relates to the discovery and isolation of a new substance found
in
Bugula neritina specimens collected from the Gulf of Mexico and herein denominated "Neristatin 1".
Neristatin 1 is an inhibitor of lymphocytic leukemia as measured by the National Cancer
Institute P388 cell line. The new substance has the structural formula:
![](https://data.epo.org/publication-server/image?imagePath=1993/10/DOC/EPNWA1/EP92307132NWA1/imgb0001)
[0002] The marine bryozoan
Bugula neritina has been found to contain a unique series of closely related macrocyclic (22-membered)
lactones known as bryostatins. Because of their very selective antineoplastic and
cytostatic activity, potent influence on protein kinase C biochemical pathways, anti-tumor
promoter effects and stimulation of bone marrow progenitor cells to form colonies
(GM-CSF activity), bryostatin 1 has been selected for clinical evaluation. Discovery
and study of a bryostatin biosynthetic precursor or degradation products has been
considered necessary to gain further mechanistic and structure/activity insights.
The isolation and structural elucidation of the first such substance, herein designated
"neristatin 1", is described herein.
[0003] The present invention relates to the discovery of a unique precursor or degradation
product of a bryostatin showing antineoplastic and cytostatic activity. Neristatin
1 has been isolated from a bryozoan,
Bugula neritina, found in the Gulf of Mexico and its structure has been elucidated by 2D-NMR and
a series of chromatographic studies.
[0004] Accordingly, an aspect of a preferred embodiment of the present invention is to isolate
and elucidate a new natural substance which has appreciable protein Kinase C affinity,
is active against the P388 murine lymphocytic leukemia cell line, and provides the
bryostatin biosynthetic precursor or degradation product necessary to gain further
mechanistic, structure and activity insights into the bryostatin series.
[0005] Another aspect of a preferred embodiment is to isolate and elucidate a novel macrocytic
lactone herein denominated "neristatin 1" derived from the naturally occurring marine
bryozoan,
Bugula neritina.
[0006] These and still further objects as shall hereinafter appear are readily fulfilled
by the present invention in a remarkably unexpected manner as will be readily discerned
from the following detailed description of an exemplary embodiment thereof.
[0007] A 1,000 kg (approximate damp wt.) recollection (1986, Gulf of Mexico Coast of Florida)
of
Bugula neritina Linnaeus was extracted with 2-propanol. Initial solvent partitioning and stearic
exclusion chromatographic procedures were conducted as previously described for the
closely related Bryozoan
Amathia convolute (See:Pettit et al.,
Tetrahedron, 1985,41,985). Separation was guided by bioassay employing the P388 lymphocytic leukemia
cell line with a combination of gel permeation (and partition on SEPHADEX LH-20) and
partition (silica gel) chromatography, high speed countercurrent distribution and
HPLC techniques to provide 8.0 mg (8.0 x 10
-2% yield) of colorless neristatin 1: mp 214-216·D; [α]
D = +98° (CH₂Cl₂, c = 0.26; R
f (silica gel) 0.62 (toluene-ethyl acetate-methanol 3:1:1); HPLC retention times, 11
min. (RP C-8 column, 10 mm x 25 cm, 80% methanol-water, 0.8 mL/min) and 9 min (normal
phase column, 10.0 mm x 25 cm, hexanemethylene chloride-methanol 14:8:1 with UV detection
at λ=254 nm); HRFABMS (with LiI) found 799.4090, calc. for C₄₁H₆₀O₁₅Li 799.4092; and
EIMS 70 eV,
m/
z, M⁺ 792 (33) calc. 792 for C₄₁H₆₀O₁₅, 774 (100%) [M-H₂O]S+S and 756 (8%) [774-H₂O]S+S.
The ¹H- and ¹³C- and HMBC-NMR values for this substance now follows.
[0008] The NMR ¹H-, ¹³C, and HMBC assignments for neristatin 1 in deuteriochloroform solution
now follows: ¹H(400MHz): 2.72 (dd, 3.7,13, H-2a), 2.37 (dd,11,13, H-2b), 4.35 (m,
became ddd, 3.7,11,11 upon the addition of D₂O; H-3), 1.84; 1.38 (m, H-4a,b), 3.67
(m, H-5), 1.65; 1.50 (m, H-6a,b), 4.81 (dd, 5,12, H-7), 2.08 (brd, 13, H-10a), 2.04
(dd, 11,13, H-10b), 3.85 (brt, 11, H-11), 2.29 (brt, 12, H-12a), 2.11 (brd, 12, H-12b),
4.00 (brd, 15, H-14a), 1.90 (brdd, 14,15, H-14b), 3.95 (brdd, 6,14, H-15), 5.63 (dd,
6,15.8, H-16), 6.42 (d, 15.7, H-17), 3.54 (ddd, 11,7.1,7.1 H-21), 1.82; 1.72 (m, H-22a,b),
4.69 (brddd, 5,10.5,11, H-23), 1.52; 1.38 (m, H-24a,b), 3.47 (ddd, 6.5,9.7,9.7, became
t, 9.7, following addition of D₂O, H-25), 4.87 (dq, 9.7,6.5, H-26), 1.09 (d, 6.5,
H-27), 0.94; 0.95 (s, H-28,29), 5.82 (brs, H-30), 1.28; 1.27 (s, H-32,33), 2.87 (dd,
11,18.5, H-34a), 2.40 (dd, 7,18.5, H-34b), 3.70 (s, OMe), 1.16 (s, H-3',4',5'), 6.09
(s, C-9 OH), 4.92 (d, 6.3, C-25 OH). ¹³C(100MHz): 169.13 (C-1), 44.87 (C-2), 66.27
(C-3), 42.94 (C-4), 66.50 (C-5), 32.94 (C-6), 73.62 (C-7), 42.31 (C-8), 101.52 (C-9),
35.42 (C-10), 74.93 (C-11), 42.08 (C-12), 155.52 (C-13), 36.18 (C-14), 77.80 (C-15),
127.50 (C-16), 136.40 (C-17), 47.99 (C-18), 203.32 (C-19), 115.20 (C-20), 40.41 (C-21),
37.24 (C-22), 77.70 (C-23), 38.25 (C-24), 71.58 (C-25), 73.86 (C-26), 16.93 (C-27),
20.94 (C-28), 14.71 (C-29), 115.20 (C-30), 166.87 (C-31), 24.83 (C-32), 26.71 (C-33),
34.19 (C-34), 174.19 (C-35), 51.16 (C-36, OMe), 178.00 (C-1'), 39.00 (C-2'), 27.11
(C-3',4',5'). HMBC(500MHz): H2a to C-1, C-3; H-7 to C-29; H-12a to C-11, C-13, C-30;
H-12b to C-13, C-30; H-14a to C-12, C-13, C-15; H-15 to C-11, C-12, C-13; H-17 to
C-15, C-18, C-19, C-32; H-28 to C-7, C-8, C-9, C-29; H-29 to C-7, C-8, C-9, C-28;
H-30 to C-12, C-14, C-31; H-32 to C-17, C-18, C-19, C-33; H-33 to C-17, C-18, C-19,
C-32; H-34a to C-21, C-20, C-35; H-34b to C-35; H-36 to C-31; H-3'-5' to C-1', C-2';
C-9 OH to C-8, C-9, C-10.
[0009] The possibility of a relationship between neristatin 1 and the bryostatins was first
suggested by the color displayed by neristatin 1 on a thin layer chromatographic plate.
However, a detailed 2D NMR study rapidly uncovered major structural differences between
the substances. Only one methoxy signal appeared in the ¹H NMR spectrum and signals
assigned using ¹H-¹H COSY and ¹H-¹³C correlated spectra demonstrated that neristatin
1 did not possess a bryopyran ring. Furthermore, in the ¹H NMR spectrum, the H-26
signal was shifted downfield at δ 4.87 and the H-25 signal shifted upfield at δ 3.47
compared with those of the bryostatins. More importantly, a doublet signal at δ 4.92
(
J = 6.3 Hz) was found coupled with the H-25 signal. The former disappeared and the
later was simplified upon addition of D₂O. Such evidence suggested that a free hydroxy
group was present at C-25 and that lactonization was involved at the C-26 position.
From the downfield shifts of the H-17 signal to δ 6.42, the H-32 and H-33 methyl signals
to δ 1.28 and 1.27 combined with a ¹³C signal at δ 203.32, a carbonyl group was assigned
to C-19.
[0010] The presence of four ¹³C ester carbonyl signals at δ 169.13, 166.87, 174.19 and 178.00
combined with results of heteronuclear band correlation (HMBC) experiments also supported
presence of a ν -lactone. The two signals at δ 40.41 (C-21). Furthermore, the C-20
to C-23 region of neristatin 1 proved refractory to rigorous 2D NMR interpre-tation
until the crystal structure analysis was in hand.
[0011] Unlike the generally stable bryostatins (except for bryostatin 3), neristatin 1 demonstrated
sensitivity to recrystallization attempts and a number of small samples rapidly degraded
in various solvents until it recrystallized unchanged from acetone-hexane. While only
relatively poor quality (cracked, vapor pockets and other imperfections) crystals
were available for the crystal structure determination, this difficulty was surmounted
and an unequivocal structure was obtained for neristatin 1 as shown below. The best
crystal (dimensions ≈ 0.18 x 0.30 x 0.40 mm) was mounted on the end of a glass capillary.
Data with very poor intensities (and markedly broadened reflections - average can
angle 2.30°) was collected to a maximum of 2ϑ=140° on an ENRAF-NONIUS CAD-4 diffractometer
at -65°C. One octant of data was collected for the orthorhombic crystal, space group
P2₁2₁2₁, with a=23.325(9), b=16.368(3), c=11.149(14)Å, V=4256.7ų, ρ
c=1.237 g cm⁻³ for Z=4. Insufficient sample was available for an accurate density measurement.
The ω/2ϑ scan technique was used with graphite monochromated Cu Ka radiation (λ 1.5418Å).
Following measurement of each reflection, the FRIEDEL equivalent reflections were
merged and systematic absences rejected. A total of 5845 unique reflections remained,
of which 2907 ((Fo). 5σ(Fo) containing FRIEDELs) were used in the subsequent structure
refinement. Direct methods was used in the
[0012] Initial application of SHELXS-86, using the default starting values, provided a complete
structure containing 56 nonhydrogen atoms. The structure was consistent with the high
field NMR data and allowed logical interpretation of the refractory (by NMR) C-20
to C-23 region. Subsequent isotropic refinement of the structure (containing 56 nonhydrogen
atoms and 60 hydrogens calculated at optimum positions and allowed to ride) with SHELXTL-PLUS
provided conventional and weighted residual indices of R=0.148 and R
w=0.146, respectively. Based on the relatively poor data and low reflection/parameter
ratio, these refinement results were not unexpected. The tendency of a number of atoms
to yield "non-positive definite" thermal parameters precluded anisotropic refinement.
Although results of the single crystal X-ray analysis were considered marginal, the
structure assigned neristatin 1, as shown below, was considered unequivocal and quite
consistent with the extensive NMR correlations and assignments reported above. Bond
lengths and angles obtained for the crystal structure of neristatin 1 fell within
generally accepted limits, except for the C₁₄-C₁₅ bond, which was longer that expected
(1.71 Å). The absolute stereochemical configuration assigned to neristatin 1, as shown,
is based upon the known absolute stereochemistry of the related bryostatins. Stereochemical
assignments for the ten chiral centers of neristatin 1 are as follows: 3(R), 5,(R),
7(S), 9(S), 15(R), 20(S), 21(S), 23(S), 25(R), 26(R).
![](https://data.epo.org/publication-server/image?imagePath=1993/10/DOC/EPNWA1/EP92307132NWA1/imgb0002)
[0013] Protein kinase C is the target for the bryostatins. The binding affinity of neristatin
1 for protein kinase C was determined by competition for [26-³H] bryostatin 4 binding,
using the conditions previously developed for measurement of highly potent bryostatins.
Under these conditions, which involve reconstitution of the enzyme in phosphatidylserine/TRITION
X-100 mixed micelles, the K
i for neristatin 1 was 124± 10nM (mean ± SEM, 4 experiments), compared to 1.3 nM for
bryostatin 4 and 12.3 nM for the typical phorbol 12,13-dibutyrate. Because of the
relatively low affinity of neristatin 1, it was also assayed under the usual phorbol
ester binding conditions using reconstitution of protein kinase C in phosphati- dylserine.
Here, the K
i of neristatin 1 was 21.2 ± 1.3 nM (mean± sem, 3 experiments), compared to 0.53 nM
phorbol 12,13-dibutyrate. Under these conditions, the 26-epimer of bryostatin 4 has
a K
d of 13 nM. The foregoing demonstrates that neristatin 1 retains appreciable affinity
for protein kinase C, albeit an order of magnitude less than that of phorbol 12,13-dibutyrate
and at least two orders of magnitude less than that of bryostatin 4.
[0014] Consistent with the binding results, neristatin 1 was active (ED₅₀ 10 µg/mL) against
the P388 cell line. The reduced but still significant potency of neristatin compared
to the bryostatin 5 was considered a considerable asset for further defining structure/activity
relationships and biochemical mechanisms among this remarkable series of biosynthetic
products.
[0015] The significance of the NCI screens and their relationship to ultimate human therapy
is well-known in the art. (See: Boyd, Status of the NCI preclinical antitumor drug
discovery screen: implications for selection of new agents for clinical trial In:
DeVita et al, CANCER:
Principals and Practices of Oncology,
undate series, Vol. 3., No. 10, Lippincott, Philadelphia, 1989, pp1-12; and Boyd et al, Data display
and analysis strategies from NCI disease oriented
in vitro antitumor drug screen. In: Valeriote et al,
Antitumor Drug Discovery and Development, Kluwer Academic Press, Amsterdam, 1990)
[0016] From the foregoing, it is readily apparent that a useful embodiment of the present
invention has been herein described and illustrated which fulfills all of the aforestated
objectives in a remarkably unexpected fashion. It is of course understood that such
modifications, alterations and adaptations as may readily occur to the artisan confronted
with this disclosure are intended within the spirit of this disclosure which is limited
only by the scope of the claims appended hereto.
1. A compound having the structural formula:
2. A composition comprising a compound according to claim 1, wherein the composition
is an inhibitor of lymphocytic leukemia as measured by The National Cancer Institute's
P 388 cell line and displays significant affinity for the NCI protein kinase C evaluation
system.
3. A method of inhibiting cell growth in NCI's P388 Murine lymphatic leukemia with a
cell growth inhibiting amount of a compound according to claim 1.
4. A compound according to claim 1, having, in deuteriochloroform solution, the following
NMR, ¹H-, ¹³C and HMBC assignments:
¹H(400MHz): 2.72 (dd, 3.7,13, H-2a), 2.37 (dd,11,13, H-2b), 4.35 (m, became ddd, 3.7,11,11
upon the addition of D₂O; H-3), 1.84; 1.38 (m, H-4a,b), 3.67 (m, H-5), 1.65; 1.50
(m, H-6a,b), 4.81 (dd, 5,12, H-7), 2.08 (brd, 13, H-10a), 2.04 (dd, 11,13, H-10b),
3.85 (brt, 11, H-11), 2.29 (brt, 12, H-12a), 2.11 (brd, 12, H-12b), 4.00 (brd, 15,
H-14a), 1.90 (brdd, 14,15, H-14b), 3.95 (brdd, 6,14, H-15), 5.63 (dd, 6,15.8, H-16),
6.42 (d, 15.7, H-17), 3.54 (ddd, 11,7.1,7.1 H-21), 1.82; 1.72 (m, H-22a,b), 4.69 (brddd,
5,10.5,11, H-23), 1.52; 1.38 (m, H-24a,b), 3.47 (ddd, 6.5,9.7,9.7, became t, 9.7,
following addition of D₂O, H-25), 4.87 (dq, 9.7,6.5, H-26), 1.09 (d, 6.5, H-27), 0.94;
0.95 (s, H-28,29), 5.82 (brs, H-30), 1.28; 1.27 (s, H-32,33), 2.87 (dd, 11,18.5, H-34a),
2.40 (dd, 7,18.5, H-34b), 3.70 (s, OMe), 1.16 (s, H-3',4',5'), 6.09 (s, C-9 OH), 4.92
(d, 6.3, C-25 OH). ¹³C(100MHz): 169.13 (C-1), 44.87 (C-2), 66.27 (C-3), 42.94 (C-4),
66.50 (C-5), 32.94 (C-6), 73.62 (C-7), 42.31 (C-8), 101.52 (C-9), 35.42 (C-10), 74.93
(C-11), 42.08 (C-12), 155.52 (C-13), 36.18 (C-14), 77.80 (C-15), 127.50 (C-16), 136.40
(C-17), 47.99 (C-18), 203.32 (C-19), 115.20 (C-20), 40.41 (C-21), 37.24 (C-22), 77.70
(C-23), 38.25 (C-24), 71.58 (C-25), 73.86 (C-26), 16.93 (C-27), 20.94 (C-28), 14.71
(C-29), 115.20 (C-30), 166.87 (C-31), 24.83 (C-32), 26.71 (C-33), 34.19 (C-34), 174.19
(C-35), 51.16 (C-36, OMe), 178.00 (C-1'), 39.00 (C-2'), 27.11 (C-3',4',5'). HMBC(500MHz):
H2a to C-1, C-3; H-7 to C-29; H-12a to C-11, C-13, C-30; H-12b to C-13, C-30; H-14a
to C-12, C-13, C-15; H-15 to C-11, C-12, C-13; H-17 to C-15, C-18, C-19, C-32; H-28
to C-7, C-8, C-9, C-29; H-29to C-7, C-8, C-9, C-28; H-30 to C-12, C-14, C-31; H-32
to C-17, C-18, C-19, C-33; H-33 to C-17, C-18, C-19, C-32; H-34a to C-21, C-20, C-35;
H-34bto C-35; H-36 to C-31; H-3'-5' to C-1', C-2'; C-9 OH to C-8, C-9, C-10.